CHF4.43
2.96% day before yesterday
SIX Swiss Exchange, Dec 23, 05:31 pm CET
ISIN
CH0363463438
Symbol
IDIA

Idorsia Stock price

CHF4.43
+1.30 41.60% 1M
+2.55 136.38% 6M
+3.60 438.32% YTD
+3.70 506.16% 1Y
-9.44 68.07% 3Y
-20.86 82.50% 5Y
-9.23 67.58% 10Y
-9.23 67.58% 20Y
SIX Swiss Exchange, Closing price Tue, Dec 23 2025
-0.14 2.96%
ISIN
CH0363463438
Symbol
IDIA
Industry

New AI Insights on Idorsia Insights AI Insights on Idorsia

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
CHF1.1b
Enterprise Value
CHF2.2b
Net debt
CHF1.1b
Cash
CHF71.2m
Shares outstanding
232.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.7 | 5.1
EV/Sales
9.5 | 10.2
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-239.6%
Return on Equity
21.8%
ROCE
-40.7%
ROIC
-37.8%
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
CHF232.5m | CHF216.1m
EBITDA
CHF-98.9m | CHF-62.7m
EBIT
CHF-123.6m | CHF-64.7m
Net Income
CHF-117.9m | CHF-84.3m
Free Cash Flow
CHF-132.6m
Growth (TTM | estimate)
Revenue
213.7% | 92.1%
EBITDA
73.3% | 80.1%
EBIT
68.6% | 80.8%
Net Income
60.2% | 68.0%
Free Cash Flow
72.9%
Margin (TTM | estimate)
Gross
86.5%
EBITDA
-42.5% | -29.0%
EBIT
-53.2%
Net
-50.7% | -39.0%
Free Cash Flow
-57.0%
More
EPS
CHF-0.5
FCF per Share
CHF-0.6
Short interest
-
Employees
650
Rev per Employee
CHF170.0k
Show more

Is Idorsia a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Idorsia Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Idorsia forecast:

1x Buy
8%
4x Hold
33%
7x Sell
58%

Analyst Opinions

12 Analysts have issued a Idorsia forecast:

Buy
8%
Hold
33%
Sell
58%

Financial data from Idorsia

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
233 233
214% 214%
100%
- Direct Costs 31 31
90% 90%
14%
201 201
249% 249%
86%
- Selling and Administrative Expenses 216 216
22% 22%
93%
- Research and Development Expense 98 98
37% 37%
42%
-99 -99
73% 73%
-43%
- Depreciation and Amortization 25 25
6% 6%
11%
EBIT (Operating Income) EBIT -124 -124
69% 69%
-53%
Net Profit -118 -118
60% 60%
-51%

In millions CHF.

Don't miss a Thing! We will send you all news about Idorsia directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus. The was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.

Head office Switzerland
CEO André Muller
Employees 650
Founded 2017
Website www.idorsia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today